Press release
Antisense & RNAi Therapeutics Market Report 2021 - SWOT Analysis, Estimated Yield, New Trends, Key Major Players, And Future Prospects
Antisense & RNAi Therapeutics Market
The antisense & RNAi therapeutics market report describes and explains the global antisense & RNAi therapeutics market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
Place A Direct Purchase Order Of The Report Here
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3389
The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.
The global antisense & RNAi therapeutics market is expected to grow from $1.11 billion in 2020 to $1.2 billion in 2021 at a compound annual growth rate (CAGR) of 8.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.79 billion in 2025 at a CAGR of 11%.
Request For The Sample Of The Antisense & RNAi Therapeutics Market Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
Some of the major players of the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics, Antisense Therapeutics Ltd., Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals), Bio-Path Holdings Inc., Calando Pharmaceuticals, Dicerna Pharmaceuticals, Enzon Pharmaceuticals Inc, Gradalis, iCo Therapeutics, miRagen Therapeutics, Olix Pharmaceuticals, OncoGeneX Pharmaceuticals, Lorus Therapeutics (Aptose Biosciences), Regulus Therapeutics, Rexahn Pharmaceuticals, Rxi Pharmaceuticals, Santaris Pharma A/S (Roche), Sarepta Therapeutics, Silence Therapeutics Plc, Sirnaomics Inc., Tekmira Pharmaceuticals, Cenix BioScience, Sirnaomics.
The countries covered in the global antisense & RNAi therapeutics market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam.
The regions covered in the global antisense & RNAi therapeutics market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The global antisense & RNAi therapeutics market is segmented -
1) By Technology: RNA Interference, Antisense RNA
2) By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other
Read More On The Global Antisense & RNAi Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-market-global-report-2020-30-covid-19-growth-and-change
Few Points From Table Of Content
1. Executive Summary
2. Antisense & RNAi Therapeutics Market Characteristics
3. Antisense & RNAi Therapeutics Market Trends And Strategies
4. Impact Of COVID-19 On Antisense & RNAi Therapeutics
5. Antisense & RNAi Therapeutics Market Size And Growth
…
27. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles
28. Antisense & RNAi Therapeutics Pipeline Analysis
29. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market
30. Antisense & RNAi Therapeutics Market Future Outlook and Potential Analysis
31. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Interested to know more about The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
The World’s Most Comprehensive Database
The Business Research Company’s flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antisense & RNAi Therapeutics Market Report 2021 - SWOT Analysis, Estimated Yield, New Trends, Key Major Players, And Future Prospects here
News-ID: 2430428 • Views: …
More Releases from The Business research company
AC-DC Power Supply Adapter Market 2024-2033: Size, Share & Competitive Landscape …
The ac-dc power supply adapter market size has grown strongly in recent years. It will grow from $14.01 billion in 2023 to $15.36 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to consumer electronics boom, globalization and trade, miniaturization and portability trends, industrial automation growth, mobile computing revolution..
The ac-dc power supply adapter market size is…
Rapid Microbiology Testing Kits Market Report 2024 - Market Size, Growth Rate, M …
"The rapid microbiology testing kits market size has grown steadily in recent years. It will grow from $4.61 billion in 2023 to $4.82 billion in 2024 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rising prevalence of infectious diseases, increasing awareness of the benefits of rapid microbiology testing, food safety concerns, growing pharmaceutical manufacturing.
The rapid microbiology testing…
Magnesite Market 2024-2033: Growth Trends, Forecast & Competitive Landscape Outl …
The magnesite market size has grown steadily in recent years. It will grow from $12.37 billion in 2023 to $12.97 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to industrialization and urbanization, steel production, global economic trends, environmental regulations, infrastructure development.
The magnesite market size is expected to see steadily grown in the next…
Oral Biologics & Biosimilar Drugs Market Competitive And Growth Analysis 2024 | …
"The oral biologics & biosimilar drugs market size has grown exponentially in recent years. It will grow from $5.94 billion in 2023 to $7.19 billion in 2024 at a compound annual growth rate (CAGR) of 21.0%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, growing awareness of oral biologics, increasing patent expirations, rising demand for biosimilars.
The oral biologics & biosimilar drugs…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
